• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苯妥英钠与磷苯妥英钠静脉给药相关的静脉刺激

Venous irritation related to intravenous administration of phenytoin versus fosphenytoin.

作者信息

Jamerson B D, Dukes G E, Brouwer K L, Donn K H, Messenheimer J A, Powell J R

机构信息

School of Pharmacy, University of North Carolina at Chapel Hill 27599-7360.

出版信息

Pharmacotherapy. 1994 Jan-Feb;14(1):47-52. doi: 10.1002/j.1875-9114.1994.tb02788.x.

DOI:10.1002/j.1875-9114.1994.tb02788.x
PMID:8159601
Abstract

STUDY OBJECTIVE

To compare the frequency, severity, and time course of venous irritation after administration of a single intravenous dose of phenytoin with an equimolar dose of fosphenytoin, a water-soluble phenytoin prodrug.

DESIGN

Randomized, double-blind, two-period, crossover study.

SETTING

University hospital clinical research unit.

PATIENTS

Twelve healthy volunteers within 15% of ideal body weight and with no clinically significant abnormalities on physical examination, medical history, or laboratory assessment.

INTERVENTIONS

Volunteers randomly received a 30-minute infusion of phenytoin sodium 250 mg (250 mg/5 ml) or an equimolar dose of fosphenytoin 375 mg (375 mg/5 ml). Subjects returned for the crossover treatment 14-21 days later.

MEASUREMENTS AND MAIN RESULTS

Subjects assessed venous irritation (pain, burning, itching), and investigators evaluated phlebitis (erythema, swelling, tenderness), induration, exudation, and cording. Phenytoin was associated with a significantly higher degree of pain at the infusion site in all subjects and a significant degree of phlebitis in eight subjects (p < 0.05); cording occurred in six subjects. The time course of phenytoin-induced phlebitis was bimodal. Erythema and tenderness were prominent at the end of the infusion and again at 24 hours. Cording was first noted between 24 hours and 1 week after infusion. In contrast, fosphenytoin was associated with mild pain in two subjects, one incident of phlebitis, and no erythema or cording.

CONCLUSIONS

Fosphenytoin administration resulted in significantly less venous irritation and phlebitis compared with an equimolar dose of phenytoin. The clinical use of this water-soluble phenytoin prodrug should minimize the frequency and severity of infusion-site reactions and should allow convenient, rapid, intravenous administration of drug, undiluted or admixed with intravenous solutions.

摘要

研究目的

比较单次静脉注射苯妥英钠与等摩尔剂量的磷苯妥英(一种水溶性苯妥英前体药物)后静脉刺激的频率、严重程度和时间进程。

设计

随机、双盲、两阶段、交叉研究。

地点

大学医院临床研究单位。

患者

12名健康志愿者,体重在理想体重的15%以内,体格检查、病史或实验室评估均无临床显著异常。

干预措施

志愿者随机接受30分钟输注250mg苯妥英钠(250mg/5ml)或等摩尔剂量的375mg磷苯妥英(375mg/5ml)。受试者在14 - 21天后返回接受交叉治疗。

测量指标及主要结果

受试者评估静脉刺激(疼痛、烧灼感、瘙痒),研究者评估静脉炎(红斑、肿胀、压痛)、硬结、渗出和条索形成。苯妥英钠在所有受试者中均与输注部位显著更高程度的疼痛相关,在8名受试者中出现显著程度的静脉炎(p < 0.05);6名受试者出现条索形成。苯妥英钠所致静脉炎的时间进程呈双峰型。红斑和压痛在输注结束时及24小时时再次出现。条索形成在输注后24小时至1周之间首次出现。相比之下,磷苯妥英钠在2名受试者中引起轻度疼痛,1例静脉炎,无红斑或条索形成。

结论

与等摩尔剂量的苯妥英钠相比,磷苯妥英钠给药导致的静脉刺激和静脉炎明显更少。这种水溶性苯妥英前体药物的临床应用应能将输注部位反应的频率和严重程度降至最低,并应允许方便、快速地静脉给药药物,无需稀释或与静脉溶液混合。

相似文献

1
Venous irritation related to intravenous administration of phenytoin versus fosphenytoin.苯妥英钠与磷苯妥英钠静脉给药相关的静脉刺激
Pharmacotherapy. 1994 Jan-Feb;14(1):47-52. doi: 10.1002/j.1875-9114.1994.tb02788.x.
2
The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.磷苯妥英在神经外科患者中肌肉注射和静脉注射后的安全性、耐受性及药代动力学。
Pharmacotherapy. 1996 Jul-Aug;16(4):638-45.
3
Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.静脉注射磷苯妥英钠在健康日本志愿者中的生物利用度。
Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):139-48. doi: 10.1007/s13318-012-0105-x. Epub 2012 Sep 12.
4
Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin.苯妥英钠或磷苯妥英钠在急诊科常规使用时不良事件及住院时间的随机评估。
Neurol Res. 2002 Dec;24(8):842-8. doi: 10.1179/016164102101200834.
5
Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.成人使用磷苯妥英的临床经验:药代动力学、安全性及疗效
J Child Neurol. 1998 Oct;13 Suppl 1:S15-8; discussion S30-2. doi: 10.1177/0883073898013001051.
6
Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.磷苯妥英:癫痫急性治疗中的临床药代动力学及比较优势
Clin Pharmacokinet. 2003;42(1):33-58. doi: 10.2165/00003088-200342010-00002.
7
Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin.需要苯妥英钠负荷剂量的患者使用肌内注射磷苯妥英(开浦兰)。
Epilepsy Res. 1997 Oct;28(3):181-7. doi: 10.1016/s0920-1211(97)00054-5.
8
Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.磷苯妥英钠静脉给药后在儿科患者、成年患者和健康志愿者中的群体药代动力学。
Eur J Clin Pharmacol. 2013 Mar;69(3):489-97. doi: 10.1007/s00228-012-1373-8. Epub 2012 Aug 24.
9
Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery.在癫痫或神经外科手术中,多次肌内注射磷苯妥英替代口服苯妥英的安全性和耐受性。
Arch Neurol. 1996 Aug;53(8):764-8. doi: 10.1001/archneur.1996.00550080082016.
10
The safety and efficacy of fosphenytoin for the treatment of status epilepticus.磷苯妥英治疗癫痫持续状态的安全性和有效性。
Expert Rev Neurother. 2015;15(9):983-92. doi: 10.1586/14737175.2015.1074523. Epub 2015 Aug 9.

引用本文的文献

1
Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations.治疗剂的盐:化学、物理化学和生物学考虑因素。
Molecules. 2018 Jul 14;23(7):1719. doi: 10.3390/molecules23071719.
2
Purple Glove Syndrome after Phenytoin or Fosphenytoin Administration: Review of Reported Cases and Recommendations for Prevention.苯妥英钠或磷苯妥英钠给药后出现的紫手套综合征:报告病例回顾及预防建议
J Med Toxicol. 2015 Dec;11(4):445-59. doi: 10.1007/s13181-015-0490-z.
3
Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.
静脉注射磷苯妥英钠在健康日本志愿者中的生物利用度。
Eur J Drug Metab Pharmacokinet. 2013 Jun;38(2):139-48. doi: 10.1007/s13318-012-0105-x. Epub 2012 Sep 12.
4
Treatment of nonconvulsive status epilepticus.非惊厥性癫痫持续状态的治疗。
Curr Treat Options Neurol. 2012 Aug;14(4):307-21. doi: 10.1007/s11940-012-0179-4.
5
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes.磷苯妥英钠治疗癫痫持续状态:基于证据对其临床和经济结果的评估
Core Evid. 2005;1(1):65-75. Epub 2005 Mar 31.
6
Recent and future advances in the treatment of status epilepticus.近期和未来对癫痫持续状态治疗的进展。
Ther Adv Neurol Disord. 2008 Jul;1(1):33-42. doi: 10.1177/1756285608094263.
7
Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.苯妥英钠和磷苯妥英钠在重症疟疾合并癫痫持续状态儿童中的药代动力学及临床效果
Br J Clin Pharmacol. 2003 Jul;56(1):112-9. doi: 10.1046/j.1365-2125.2003.01829.x.
8
Managing status epilepticus. New drug offers real advantages.癫痫持续状态的管理。新药具有真正的优势。
BMJ. 2000 Apr 8;320(7240):953-4. doi: 10.1136/bmj.320.7240.953.
9
Fosphenytoin. Pharmacoeconomic implications of therapy.磷苯妥英钠。治疗的药物经济学影响。
Pharmacoeconomics. 1998 Dec;14(6):685-90. doi: 10.2165/00019053-199814060-00008.